Skip to main content
رجوع
BCRX logo

BioCryst Pharmaceuticals, Inc.

جودة البيانات: 100%
ذروة شراء
BCRX
NASDAQ Healthcare Biotechnology
KWD 9.80
▲ KWD 0.10 (1.03%)
القيمة السوقية: 2.06B
نطاق اليوم
KWD 9.63 KWD 10.04
نطاق 52 أسبوعًا
KWD 6.00 KWD 11.31
حجم التداول
7,240,678
متوسط 50 يوم / 200 يوم
KWD 7.53 / KWD 7.94
الإغلاق السابق
KWD 9.70

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 7.8 0.4
P/B 2.9
ROE % 3.7
Net Margin % 30.2 3.8
Rev Growth 5Y % 53.6 10.0
D/E 0.2

النقاط الرئيسية

Revenue grew 53.60% annually over 5 years — strong growth
Net margin of 30.16% shows strong profitability
Generating 327.41M in free cash flow
P/E of 7.80 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 40.50%
Cash machine — converts 124.09% of earnings into free cash flow

النمو

Revenue Growth (5Y)
53.60%
Revenue (1Y)94.10%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROIC71.40%
Net Margin30.16%
Op. Margin38.98%

الأمان

Debt / Equity
N/A
Current Ratio2.06
Interest Coverage4.32

التقييم

P/E Ratio
7.80
P/B RatioN/A
EV/EBITDA7.17
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 94.10% Revenue Growth (3Y) 62.47%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 53.60% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 874.84M Net Income (TTM) 263.86M
ROE N/A ROA 51.32%
Gross Margin 97.82% Operating Margin 38.98%
Net Margin 30.16% Free Cash Flow (TTM) 327.41M
ROIC 71.40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.06
Interest Coverage 4.32 Dividend Yield 0.00%
Valuation
P/E Ratio 7.80 P/B Ratio N/A
P/S Ratio 2.35 PEG Ratio -0.02
EV/EBITDA 7.17 Dividend Yield 0.00%
Market Cap 2.06B Enterprise Value 2.44B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 874.84M 450.71M 331.41M 270.83M 157.17M
Net Income 263.86M -88.88M -226.54M -247.12M -184.06M
EPS (Diluted) 1.21 -0.43 -1.18 -1.33 -1.03
Gross Profit 855.76M 438.23M 326.75M 264.23M 149.91M
Operating Income 340.99M -2.54M -103.71M -148.44M -177.72M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 514.16M 490.42M 516.96M 550.00M 588.15M
Total Liabilities 633.31M 966.35M 972.49M 844.60M 695.14M
Shareholders' Equity -119.15M -475.93M -455.53M -294.60M -106.99M
Total Debt 477.33M 841.42M 825.15M 741.45M 593.24M
Cash & Equivalents 89.74M 104.92M 110.64M 304.77M 504.39M
Current Assets 404.35M 421.97M 495.97M 516.50M 566.14M
Current Liabilities 196.07M 160.38M 149.99M 105.51M 103.72M